In patients with 2.50–4.00 ng/mL PSA, the status of PCa is not clear, and studies have emphasized that re-adjustment of the cutoff value for PSA levels may be necessary [5–8]. This evidence concerns the gene KLK3 and posterior cortical atrophy.